Do you offer adjuvant osimertinib to EGFR exon 19 deleted patients with T2N0 NSCLC treated with definitive SBRT?

Given the fairly striking benefit of ADAURA in resected patients, there likely would be a locoregional and distant control and likely survival benefit to this approach but we don't have data to support this. PACIFIC-4 is currently enrolling. Study of durvalumab vs placebo in patients with early stag...

Recent press release data (presumably to be presented at an upcoming meeting) states that there is a survival benefit for adjuvant osimertinib in the ADAURA study. That said, I do not offer adjuvant osimertinib to EGFR exon 19 deleted patients with T2N0 disease following SBRT. This certainly warrant...